Clinical Trials in San Antonio, Texas
33 recruiting
Showing 1–20 of 98 trials
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Metastatic Solid TumorSolid Tumor, AdultUnresectable Solid Tumor+1 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma (Skin)+2 more
AstraZeneca60 enrolled11 locationsNCT07115043
Recruiting
Phase 1Phase 2
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844
Recruiting
National Cancer Institute "Cancer Moonshot Biobank"
Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled154 locationsNCT04389632
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled149 locationsNCT07060807
Recruiting
Phase 1
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Advanced Solid TumorAdvanced Breast CancerAdvanced Ovarian Cancer
Bristol-Myers Squibb234 enrolled21 locationsNCT06997029
Recruiting
Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer914 enrolled43 locationsNCT06131840
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled257 locationsNCT06312176
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled250 locationsNCT06841354
Recruiting
Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca895 enrolled283 locationsNCT04862663
Recruiting
Phase 1Phase 2
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
HR+ Breast Cancer
NiKang Therapeutics, Inc.205 enrolled14 locationsNCT07029399
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled30 locationsNCT06638307
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336